CN111183159B - 靶向cd137的抗体及其使用方法 - Google Patents

靶向cd137的抗体及其使用方法 Download PDF

Info

Publication number
CN111183159B
CN111183159B CN201880065319.9A CN201880065319A CN111183159B CN 111183159 B CN111183159 B CN 111183159B CN 201880065319 A CN201880065319 A CN 201880065319A CN 111183159 B CN111183159 B CN 111183159B
Authority
CN
China
Prior art keywords
seq
antibody
sequence
amino acid
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880065319.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111183159A (zh
Inventor
迪·贡德
马蒂亚斯·布洛克
克里斯蒂安·赫斯
亚历山大·西莫南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numa Therapeutic Co ltd
Original Assignee
Numa Therapeutic Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195780.6A external-priority patent/EP3470428A1/en
Application filed by Numa Therapeutic Co ltd filed Critical Numa Therapeutic Co ltd
Publication of CN111183159A publication Critical patent/CN111183159A/zh
Application granted granted Critical
Publication of CN111183159B publication Critical patent/CN111183159B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880065319.9A 2017-10-10 2018-10-09 靶向cd137的抗体及其使用方法 Active CN111183159B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17195780.6A EP3470428A1 (en) 2017-10-10 2017-10-10 Antibodies targeting cd137 and methods of use thereof
EP17195780.6 2017-10-10
EP18167092 2018-04-12
EP18167092.8 2018-04-12
EP18180815 2018-06-29
EP18180815.5 2018-06-29
PCT/EP2018/077514 WO2019072870A1 (en) 2017-10-10 2018-10-09 ANTIBODIES TARGETING CD137 AND METHODS OF USE

Publications (2)

Publication Number Publication Date
CN111183159A CN111183159A (zh) 2020-05-19
CN111183159B true CN111183159B (zh) 2024-09-03

Family

ID=63834023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065319.9A Active CN111183159B (zh) 2017-10-10 2018-10-09 靶向cd137的抗体及其使用方法

Country Status (11)

Country Link
US (1) US11578133B2 (enExample)
EP (1) EP3694880A1 (enExample)
JP (1) JP7438939B2 (enExample)
KR (1) KR102907326B1 (enExample)
CN (1) CN111183159B (enExample)
AU (1) AU2018348431B2 (enExample)
CA (1) CA3075337A1 (enExample)
IL (1) IL273841B2 (enExample)
MA (1) MA50354A (enExample)
SG (1) SG11202003111SA (enExample)
WO (1) WO2019072870A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
CN110709418B (zh) * 2017-06-05 2023-09-26 努玛治疗有限公司 新型抗hsa抗体
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
BR112021026309A2 (pt) * 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
WO2021013142A1 (zh) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 抗4-1bb抗体、其抗原结合片段及双特异性抗体
CN117843786A (zh) 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
IL295382B1 (en) * 2020-02-12 2026-08-01 Chugai Seiyaku Kk Anti-CD137 antigen-binding molecule for use in cancer treatment
JP7715722B2 (ja) * 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
AU2022233547A1 (en) * 2021-03-09 2023-09-28 BioNTech SE Multispecific binding agents against cd40 and cd137 in therapy
US20250002599A1 (en) * 2021-09-03 2025-01-02 Novarock Biotherapeutics, Ltd. Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof
KR102647506B1 (ko) 2022-02-22 2024-03-13 방윤배 실내 벽체 고정용 골조보강패널
PE20260551A1 (es) * 2023-05-19 2026-03-04 Numab Therapeutics AG Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029445A1 (en) * 1998-11-17 2000-05-25 Lg Chemical Limited Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
CN105940014A (zh) * 2013-10-25 2016-09-14 努马布有限公司 双特异性构造及其在治疗各种疾病中的用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
JP2006500921A (ja) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー ヒト４−１ｂｂに対するヒト化抗体
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029445A1 (en) * 1998-11-17 2000-05-25 Lg Chemical Limited Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
CN105940014A (zh) * 2013-10-25 2016-09-14 努马布有限公司 双特异性构造及其在治疗各种疾病中的用途

Also Published As

Publication number Publication date
WO2019072870A1 (en) 2019-04-18
JP2020537520A (ja) 2020-12-24
IL273841B2 (en) 2026-03-01
CN111183159A (zh) 2020-05-19
EP3694880A1 (en) 2020-08-19
US20200332015A1 (en) 2020-10-22
CA3075337A1 (en) 2019-04-18
KR20200063153A (ko) 2020-06-04
SG11202003111SA (en) 2020-05-28
AU2018348431B2 (en) 2025-10-02
US11578133B2 (en) 2023-02-14
KR102907326B1 (ko) 2025-12-31
IL273841A (en) 2020-05-31
IL273841B1 (en) 2025-11-01
JP7438939B2 (ja) 2024-02-27
MA50354A (fr) 2020-08-19
AU2018348431A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
US12202911B2 (en) Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
US11578133B2 (en) Antibodies targeting CD137 and methods of use thereof
EP3470426A1 (en) Multispecific antibody
EP3470428A1 (en) Antibodies targeting cd137 and methods of use thereof
CN111225926B (zh) 靶向pdl1的抗体及其使用方法
EP3470429A1 (en) Antibodies targeting pdl1 and methods of use thereof
EP3636320A1 (en) Antibodies targeting cd137 and methods of use thereof
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant